诺思格收盘下跌3.10%，滚动市盈率31.19倍，总市值43.74亿元

Group 1 - The core viewpoint of the articles indicates that Norsg has a closing price of 45.29 yuan, down 3.10%, with a rolling PE ratio of 31.19 times and a total market value of 4.374 billion yuan [1] - Norsg ranks 23rd in the medical services industry, which has an average PE ratio of 46.29 times and a median of 47.83 times [1][2] - As of February 28, 2025, Norsg has 5,105 shareholders, a decrease of 336 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2 - Norsg's main business is providing comprehensive drug clinical research and development services to global pharmaceutical companies and research institutions, including clinical trial operation services, site management services, data management and statistical analysis services, biological sample testing services, clinical trial consulting services, and clinical pharmacology services [1] - In the latest financial report for 2024, Norsg achieved an operating income of 744 million yuan, a year-on-year increase of 3.14%, and a net profit of 140 million yuan, a year-on-year decrease of 13.73%, with a sales gross margin of 37.09% [1]